An Observational Study to Assess Nirsevimab Immunization Rates in Eligible Infants During Their First RSV Season in the Czechia
Recruiting
Observational Study
RSV Immunization
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 250 (estimated)
- Sponsor
- Sanofi · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The primary objective of this study is to determine the nirsevimab immunization rate in eligible infants in their first RSV-season in Czechia.
The study will focus on:
1. Assessing nirsevimab immunization rates among eligible infants (according to ČVS recommendation) in their first RSV-season in Czechia (i.e. across all geographies)
2. Assessing nirsevimab immunisation rates among the "catch-up …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Be a parent of an infant born between April 2025/26 and March 2026/27, respectively
* Permanent residence in Czechia at the time of survey completion and speak Czech
* Be at least 18 years old at the time of survey completion
* Agree with privacy policy and AE (Adverse Event) …
Contacts
Trial Transparency email recommended (Toll free for US & Canada)
800-633-1610
CONTACT